JSB462 clinical trials
Also written JSB462.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2025
How each study uses JSB462 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test JSB462.
- Dec 2026An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Phase 2 · Novartis Pharmaceuticals
- Jan 2027A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate CancerPhase 1 · Novartis Pharmaceuticals
- Jul 2027A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Phase 2 · Novartis Pharmaceuticals
Studies
Open first, then newest update. How each study uses JSB462 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Active, not recruitingPhase 2Novartis PharmaceuticalsNCT06991556Written as JSB462
- A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Active, not recruitingPhase 2Novartis PharmaceuticalsNCT07047118Written as JSB462
- A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate CancerActive, not recruitingPhase 1Novartis PharmaceuticalsNCT07174063Written as JSB462